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Summary: The present paper shows that tetrahydronorharmane (tetrahydro-0-carboline) exists in human platelets.
The concentration of tetrahydronorharmane in platelets from 10 ml platelet rich plasma was in the range of 9.3 to
25.6 pmol (n=8). Ingestion of tryptamine hydrochloride (n=4) three times daily for three consecutive days and of
19.6 mmol Z)^-tryptophan (n=7) the evening (10 p. m.) before the blood collection did not lead to an increase of
tetrahydronorharmane in platelets.
Nachweis von Tetrahydronorharman (Tetrahydro-ß-carbolin) in menschlichen Thrombocyten
Zusammenfassung: In der vorliegenden Arbeit wird das Vorkommen von Tetrahydronorharman (Tetrahydro-j3-
carbolin) in menschlichen Thrombocyten nachgewiesen. Der Gehalt der Thrombocyten aus 10 ml plättchenreichem
Plasma an Tetrahydronorharman lag in dem Bereich von 9,3 bis 25,6 pmol (n=8). Einnahme von Tryptaminhydro-
chlorid (n=4) dreimal täglich über einen Zeitraum von drei Tagen und von 19,6 mmol £>,Z,-Tiyptophan (n=7) am
Abend (22°°) vor der Blutabnahme führte nicht zu einer Zunahme des Tetrahydronorhormon-Gehalts in den
Thrombocyten.
Introduction
There is good evidence that tetrahydronorharmane
exists in the urine of man and rats as well as in the fore-
brain of rats (1,2). Tetrahydronorhamane produces
pharmacological effects in rats, which are similar to
those of serotonin-like drugs and antagonistic to those
of dopamine (3). Furthermore it could be established in
in vivo and in vitro experiments that tetrahydrpnor-
harmane inhibits high affinity uptake of serotonin and
noradrenaline into a synaptosome-rich fraction from the
brain of rats and mice (4, 5, 6). Moreover, tetrahydro-
norharmane apparently increases the release of serotonin
from brain slices of rats, whereas a release of dopamine is
inhibited (7), With respect to the uptake, storage and
metabolism of serotonin and catecholamines, blood
platelets have quite similar properties to those of
neuronal tissue. Therefore, it seems of interest to in-
vestigate whether tetrahydronorharmane is a physio-
logical constituent of human platelets and can be used
as a peripheral indicator of central mechanisms.
Materials and Methods
Tryptamine-HGI and A£-tryptophan were purchased from
Merck AG, Darmstadt, FRG, [3H]acetic anhydride 126-
296 GBq/mmol (3, 4-8 Ci/mmol) from Amersham Buchler,
Braunschweig, FRG. Tetrahydronorharmane was synthesized
using the method of Vejdelek et al. (1961) and described
elsewhere (4, 8).
Blood platelets were obtained from physically and mentally
healthy volunteers (age 27—53 years of both sexes). In one
series of experiments the subjects ingested 19,6 mmol/),£,-
tryptophan the evening before (10 p. m.) collection of the
blood samples.
In another experiment a group of 8 persons received the
same meals and beverages for three consecutive days. The food
consisted of various kind s of meat, vegetables, fruits, bread etc.
Tea and coffee served as beverages. Alcohol was not allowed. In
addition to each breakfast, lunch, and dinner 4 subjects of this
group ingested 1 mmol tryptamine hydrochloride for three
days.
Preparation of platelets
Blood samples were collected at 8 a.m. by dropping venous
blood (25 ml) from the cannula into plastic tubes containing
5 ml of ACD-stabilizer (USP X VIII formula B) as anticoagulant,
the samples were centrifuged for 30 min at 180 £ at 25°C. A
constant aliquot of platelet-rich plasma (10 ml) was removed,
and the number of platelets was counted (280-320· 109/1)
Thereafter the platelet-rich plasma was further fractionated
by centrifugatipn for 15 min at 12 000 g to give the platelet
pellet and the plasma.
Assay
The platelet pellet was homogenized by sonication in 3 ml tri-
chloroacetic acid (50 g/1 0.01 mol/1 HC1) containing 28.3 Mmol
semicarbazide HOL After centrifugation at 17 000 g for 10 min
the supernatant was transferred to a glass-stoppered 50 ml centri-
fuge tube. The residue was washed with 3.5 ml 0.1 mol/1 HC1
and the suspension centrifuged again. Both supernatants were
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combined and made basic (pH 10.3) with NaOH and saturated
with NaCl. This mixture was extracted twice with 30 ml each of
nitrogen-saturated diethylether, pretreated with semicarbazide
HC1. The organic phase was transferred to another test tube
and evaporated. The dried residue was dissolved in 200 μΐ
methanol and spotted on silica gel TLC-plates (Merck) in a line
(15 cm) under nitrogen. The tubes were washed twice with
200 μΐ diethylether which was added to the spot. For identific-
ation purposes authentic tetrahydronorharmane was spotted
separately on the plate.
Thin layer chromatography
The plates were developed in the solvent system chloroform/
acetone/diethylamine (volumes, 50ml + 40ml + 10 ml). In a
previous study, the possibility was excluded that, under the
experimental conditions used, various amines and other physio-
logically occurring substances interfered with tetrahydronor-
harmane (1). Also dopamine, noradrenaline, and adrenaline have
different Rf values in the applied solvent system. The area which
ran isographic to authentic tetrahydronorharmane was scraped
off. After the addition of 1.5 ml water saturated with NaCl and
adjusted to pH 10.3 with sodium hydrogencarbonate the
compound was eluted into 6 ml distilled diethylether. An aliquot
of 5 ml of the organic phase was transferred to a glass stoppered
vial and evaporated to dryness under a stream of nitrogen. There-
after, the sample was acetylated by a solution of 15 nmol [3HJ-
acetic anhydride (185 GBq/mmol) in 245 μΐ distilled benzene and
5 μΙ pyridine. The samples were incubated for 45 min at 75 °C in
a glycerol bath. The organic phase was evaporated to dryness and
the residue taken up in 1 ml saturated NaCl solution, pH 10.3,
containing Na2COa. The mixture was vortexed and treated
with 6 ml distilled diethylether. The organic phase was removed
and dried under a stream of nitrogen. The residue was dissolved
in 200 μΐ of methanol. The solution was spotted on silica gel
plates together with unlabelled N-acetylated tetrahydronorharmane
as carrier. The plate was developed again by chloroform/acetone/
diethylamine (volumes, 50 ml + 40 ml + 10 ml). In control
experiments it was shown that the carrier did not become
labelled by tritium exchange during chromatography.
N-acetyl-tetrahydronorharmane was made visible by UV-light
at 254 nm. The area which ran isographic with the carrier was
scraped off and transferred to a scintillation vial containing
1 ml methanol to elute tetrahydronorharmane from silica geL
Thereafter, the radioactivity of the sample was determined by
liquid scintillation spectroscopy (Packard 3380). Samples which
contained water instead of platelets were run through the whole
procedures for blank values.
The amount of tetrahydronorharmane in the platelets was
calculated by an external standard method. Two samples of
authentic tetrahydronorharmane (58 and 116 pmol) were ace-
tylated in duplicate as described above. In control experiments, it
had been ascertained that the acetylation of tetrahydronor-
harmane by radiolabelled acetic anhydride proceeds approximately
linearly from 5.8 to 1160 pmol tetrahydronorharmane.
For the determination of the recovery of tetrahydronorharmane
different amounts of authentic tetrahydronorharmane were added
to the platelet samples. These samples were run through the whole
procedure.
Results
Tetrahydronorharmane is a physiological constituent of
human platelets. Table 1 demonstrates the tetrahydro-
norharmane content in platelets of 8 healthy subjects.
Ingestion of tryptophan or tryptamine obviously did not
lead to an increase of tetrahydronorharmane.
The blank values showed good reproducibility and their
deviation was low (400 ± 13 Bq; n^6). By the method
Tab. 1. Tetrahydronorharmane (pmol) in human platelets isolated
from 10 ml platelet-rich plasma. The control subjects were not on
a diet. Four subjects ingested 1 mmol tryptamine hydrochloride
after breakfast, lunch and dinner for three consecutive days.
7 subjects received 19.6 mmol/),I-tryptophan the evening
(10 p.m.) before collection of the blood samples. Values in
parentheses are from repeated determinations.
Control Tryptamine bad Tryptophan load
M.B. 9 25.8
C.F.9 10.3as. d 7.7
R.K. 9 22.5 (22.2-22.6)
H.C. d 10.0 9.4
H.R. d 48.6












χ ± s 15.2 ± 9.1 19.8 22.7 ± 10.0
applied the smallest amount of endogenous tetrahydro-
norharmane labelled with [?H]acetic anhydride was easily
detectable. Approximately 400 Bq (net amount) is equiv-
alent to 5.8 pmol tetrahydronorharmane.
The extraction efficiency of tetrahydronorharmane (n=5)
ranged between 51 and 55%. The tetrahydronorharmane
concentrations presented were corrected for recovery.
The tetrahydronorharmane content in plasma is not
listed in the table since the recovery varied between
23 and 45%. Considering these variations the content
of tetrahydrpnorharmane in 10 ml plasma is in the same
order of magnitude as that in the platelets of the re-
spective volume of plasma.
Discussion
Tetrahydronorharmane is formed in vitro by conden-
sation of tryptamine with formaldehyde (9,10,11,12).
Both substances are present in the mammalian organism
(13,14). Therefore, it was conceivable that the syn-
thesis of tetrahydronorharmane also occurs in human
tissue. In fzctHonecker et al. (1) ascertained the
presence of tetrahydronorharmane not only in rat brain
but also in human urine. The identification of the sub-
stance was confirmed by chromatography in different
solvent systems, cocrystallisation, isotope dilution, and
mass spectroirietry (1). The amount of 9.3 to 25 pmol
tetrahydronorharmane in platelets isolated from 10 ml
plateletsrich plasma is low compared with that of sero-
tonin, but is in the same order s the amount of catechol-
amines (15,16). On account of the low concentration of
tetrahydroftorharmane in the platelets a mass spectrum
could not be performed. But because an identical method-
ological procedure was used for tetrahydronorhannane
determination in urine and platelets it is certain that the
measured compound represents tetrahydronorharmane.
It is likely that the storage sites create a concentration
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gradient between platelets and plasma for tetrahydro-
norharmane, which is mainly transported into the
platelets by diffusion as described for catecholamines
by DaPrada & Picotti (16).
In rats tryptophan (735 μιηοΐ/kg) and tryptamine (765
μπιοΐ/kg) caused a twofold and twentyfold increase of
tetrahydronorharmane concentration in the forebrain
90 min after i.p. administration (1).
In humans, however, Ingestion of tryptophan (19.6
mmol £)^-tryptophan, the evening before the collection
of blood) or of tryptamine (1 minol in the morning,
noon, and evening for three consecutive days) did not
lead to an increase of tetrahydronorharmane in platelets.
The failure of the tryptophan or tryptamine load to
induce an increase of the concentration of tetrahydro-
norharmane in men may be explained by the lower
doses of the precursor applied, compared to the ex-
periments with rats.
Since it remains to be elucidated whether tetrahydronor-
harmane acts by itself or by modulating the effects of
biogenic amines, it is not clear whether the amount of
tetrahydronorharmane is high enough to exert any func-
tion. However, it is conceivable that alterations of the
content of tetrahydronorharmane in platelets reflect:
changes in the brain. Studies to investigate tetrahydro-
norharmane in platelets of patients with mental disorders
are in progress.
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